Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry
| Autor: | Leopoldo Pérez de Isla, Gonzalo Díaz-Soto, Adriana Saltijeral, Francisco Fuentes, José Luis Díaz-Díaz, Raimundo de Andrés, Pedro Mata, Lina Badimon, José Miguel Pinilla, Daniel Zambón, José Pastor, Nelva Mata, Xavier Pintó, Rodrigo Alonso, Ovidio Muñiz |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Adolescent Familial hypercholesterolemia Treatment goals 030204 cardiovascular system & hematology Hyperlipoproteinemia Type II 03 medical and health sciences 0302 clinical medicine Interquartile range Internal medicine medicine Humans Goal achievement Prospective Studies Registries 030212 general & internal medicine Child Prospective cohort study Ldl cholesterol business.industry Anticholesteremic Agents Incidence Incidence (epidemiology) Cholesterol LDL General Medicine medicine.disease Treatment Outcome Endocrinology Spain Female lipids (amino acids peptides and proteins) Guideline Adherence National registry business Follow-Up Studies |
| Zdroj: | Revista Española de Cardiología (English Edition). 70:444-450 |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/j.rec.2016.10.010 |
| Popis: | Introduction and objectives Little is known about the characteristics of persons with familial hypercholesterolemia (FH) younger than 18 years, the lipid-lowering therapy used in these patients, and the lipid goals reached in real life. Our aim was to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients younger than 18 years enrolled in a large national registry. Methods We analyzed patients younger than 18 years enrolled in a large ongoing registry of molecularly-defined patients with FH in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was analyzed in relation to the use of lipid-lowering therapy. Results We enrolled 392 individuals younger than 18 years. Of these, 217 were molecularly-diagnosed FH patients and had a complete follow-up. The median follow-up time was 4.69 years (interquartile range, 2.48-6.38 years), 68.2% of FH patients were on statins, and 41.5% patients had LDL-C Conclusions This study shows that a high proportion of FH patients younger than 18 years have high LDL-C levels and fail to achieve recommended LDL-C targets. Statin use was the only independent predictor of LDL-C goal achievement. No safety concerns were detected during follow-up. These results indicate that many FH patients are not adequately controlled and that there is still room for treatment improvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect